<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02391441</url>
  </required_header>
  <id_info>
    <org_study_id>METc2014/134</org_study_id>
    <nct_id>NCT02391441</nct_id>
  </id_info>
  <brief_title>Ventricular Reversed Remodeling After LTX in PAH Patients</brief_title>
  <acronym>PAH-LTX</acronym>
  <official_title>Imaging of Ventricular Reversed Remodeling After Double Lung Transplantation in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate ventricular reversed remodelling after double lung
      transplantation (LTX) in patients with pulmonary arterial hypertension (PAH), measured with
      cardiac magnetic resonance imaging (MRI). Reversed remodelling will be compared with control
      patients without PAH (e.g. Cystic Fibrosis) who will also undergo LTX.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, pre-LTX and six-months post-LTX measurements will be compared with each other
      and between the primary and control group.

      Pre- and post-LTX measurements include:

      Past medical history: Including basic diagnosis; interventions, surgery and transplant
      related complications (re-operations, hospitalizations, infections) and medication history;
      These data will be collected by studying the medical files including surgical reports.

      Present medical history: Including NYHA class.

      Physical examination: Including length and weight.

      Cardiac Magnetic Resonance Imaging:

        -  Ventricular volume, function and mass measurements

        -  Flow measurements of the pulmonary artery and aorta

        -  Disease specific measurements (e.g. septal bowing, RV trabecularisation, etc.)

        -  T1-mapping

      Transthoracic Echocardiography

      Resting ECG: Disease specific electrophysiological findings (e.g. QRS-duration, right bundle
      branch block).

      Laboratory evaluation:

        -  NT-pro-BNP

        -  eGFR

        -  Remaining serum will be stored.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute increase in RV ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute increase in LV ejection fraction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute decrease in RV myocardial mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute increase in LV myocardial mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute decrease in RV end-diastolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Absolute increase in LV end-diastolic volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Restoration of septal displacement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Decrease in RV myocardial extracellulair volume assessed with T1-mapping</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ventricular remodeling on cardiac magnetic resonance</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Decrease in LV end-systolic eccentricity index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Increase in tricuspid annular plane systolic excursion (i.e. TAPSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Increase in myocardial performance index (MPI) or Tei index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Increase in tricuspid annular systolic motion velocity (i.e. RV s')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Increase in RV (global/septal/free wall) longitudinal strain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Decrease in RA size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional remodeling patterns after LTX, assessed with echocardiography</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Increase in LA size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart failure biomarkers</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Decrease in NT pro-BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic remodeling</measure>
    <time_frame>Six months postoeprative</time_frame>
    <description>Normalization of RV hypertrophy and strain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic remodeling</measure>
    <time_frame>Six months postoeprative</time_frame>
    <description>Normalization of right axis deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic remodeling</measure>
    <time_frame>Six months postoeprative</time_frame>
    <description>Normalization of right atrial enlargement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional outcome</measure>
    <time_frame>Six months postoperative</time_frame>
    <description>Decrease in NYHA-class</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
    <description>Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Control patients without increased pulmonary artery pressure (i.e. RV peak pressure &lt;35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary arterial hypertension and control patients without increased
        pulmonary artery pressure who are on the waiting list for double-LTX
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients who are on the waiting list for double-LTX, in our institution, for pulmonary
             arterial hypertension.

          -  Eligible for CMR imaging

          -  No claustrophobia

          -  No pacemaker, ICD, etc.

          -  Informed consent

        Exclusion criteria:

          -  Inability to comply with primary endpoint measures.

          -  Body mass index ≥40 kg/m2.

          -  Pregnant patients will not be included, they may be included &gt;3 months after
             pregnancy.

          -  Patients with age &lt;18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk J van Veldhuisen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>J.P. van Melle</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Pulmonary</keyword>
  <keyword>Arterial</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Lung</keyword>
  <keyword>Transplantation</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

